hepatocellular carcinoma
Conditions
Interventions
None listed
Sponsors
Chiba University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Presence of histologically confirmed or clinically diagnosed hepatocellular carcinoma 2) At least 1 target lesion measurable 3) 20 years or more 4) Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 to 2 5) Child-Pugh classification A or B 6) Life expectancy of at least 12 weeks 7) Written informed consent
Exclusion criteria
Exclusion criteria: 1) Cre <= ULN x 1.5 2) Severe cardiac disease 3) Severe cerebrovascular disease 4) interstitial pneumoniae 5) Active infection(except HBV and HCV infection) 6) Dynamic CT or EOB-MRI cannot be performed 7) Pregnant or lactating woman 8) Any patients judged by the investigator to be unfit to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Antitumor effect of each nodule after 3 months of TACE | — |
Secondary
| Measure | Time frame |
|---|---|
| Response rate Time to Progression Overall Survival Incidence rate of adverse events severity of vascular damage | — |
Countries
Japan
Contacts
Public ContactWakamatsuToru
Chiba University Hospital Department of Gastroenterology
Outcome results
None listed